Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.

"Declarations Conflict of interestSatoshi Mochida received lecture fees from Gilead Sciences, Inc., AbbVie GK., ASKA Pharmaceutical Co., Ltd., Toray Industries Inc., Otuska Pharmaceutical Co., Ltd. and Eisai Co., Ltd. Masayuki Kurosaki received lecture fees from Gilead, AbbVie, Eisai, Chugai, AstraZeneca, Lilly and Takeda. Norifumi Kawada received research grants from AstraZeneca plc., Bristol Myers Squibb., Glaxosmithkline plc., MSD co., ltd., Gilead Sciences. Inc. and NovoNordisk pharma Ltd., scholarship grants from AbbVie GK, Eisai Co., Ltd. and Otsuka Pharmaceutical Co. and received lecture fees from AbbVie GK, Gilead Sciences, Inc. and MSD Co., Ltd. Goki Suda received research grants from Gilead Sciences Inc. Hitoshi Yoshiji received lecture fees from Gilead Sci. Naoya Kato received research grants from AbbVie G.K., scholarship grants from Gilead Sciences Inc., and lecture fees from Gilead Sciences, Inc. and AbbVie G.K. Taro Takami received lecture fees from Gilead Sciences, Inc. Yasuhiro Asahina belongs to a donation-funded department funded by Fujirebio Inc. and Abbott Japan LLC. Yoshito Itoh received research grants from Merck Sharp and Dohme., scholarship grants from AbbVie Inc. and Takeda Pharm. Co.Ltd. and lecture fees from AbbVie Inc and Gilead Sciences Inc. Shuji Terai received lecture fees from Otsuka, AbbVie, Asuka, Daiichisankyo, Chiomu Takedansen and Gilead. Yoshiyuki Ueno received lecture fees from AbbVie Inc. Norio Akuta received lecture fees from AbbVie Inc. Tetsuo Takehara received research grants and lecture fees from AbbVie GK. and Gilead Sciences, Inc. All other authors declare that they have no conflicts of interest to disclose. Trial registration numberUniversity Hospital Medical Information Network (UMIN: 36150). Conflict of interest Satoshi Mochida received lecture fees from Gilead Sciences, Inc., AbbVie GK., ASKA Pharmaceutical Co., Ltd., Toray Industries Inc., Otuska Pharmaceutical Co., Ltd. and Eisai Co., Ltd. Masayuki Kurosaki received lecture fees from Gilead, AbbVie, Eisai, Chugai, AstraZeneca, Lilly and Takeda. Norifumi Kawada received research grants from AstraZeneca plc., Bristol Myers Squibb., Glaxosmithkline plc., MSD co., ltd., Gilead Sciences. Inc. and NovoNordisk pharma Ltd., scholarship grants from AbbVie GK, Eisai Co., Ltd. and Otsuka Pharmaceutical Co. and received lecture fees from AbbVie GK, Gilead Sciences, Inc. and MSD Co., Ltd. Goki Suda received research grants from Gilead Sciences Inc. Hitoshi Yoshiji received lecture fees from Gilead Sci. Naoya Kato received research grants from AbbVie G.K., scholarship grants from Gilead Sciences Inc., and lecture fees from Gilead Sciences, Inc. and AbbVie G.K. Taro Takami received lecture fees from Gilead Sciences, Inc. Yasuhiro Asahina belongs to a donation-funded department funded by Fujirebio Inc. and Abbott Japan LLC. Yoshito Itoh received research grants from Merck Sharp and Dohme., scholarship grants from AbbVie Inc. and Takeda Pharm. Co.Ltd. and lecture fees from AbbVie Inc and Gilead Sciences Inc. Shuji Terai received lecture fees from Otsuka, AbbVie, Asuka, Daiichisankyo, Chiomu Takedansen and Gilead. Yoshiyuki Ueno received lecture fees from AbbVie Inc. Norio Akuta received lecture fees from AbbVie Inc. Tetsuo Takehara received research grants and lecture fees from AbbVie GK. and Gilead Sciences, Inc. All other authors declare that they have no conflicts of interest to disclose."

"Funding Open access funding provided by Osaka University. This study was partially supported by a Grant-in-Aid for Research on Hepatitis from the Japan Agency for Medical Research and Development (JP23fk0210113) and Gilead Sciences, Inc."

"The institutional review board (IRB) at each participating hospital approved the protocol of this study (IRB No. 18431), and this study was performed in accordance with the Declaration of Helsinki as amended in 2013. In principle, informed consent was obtained from participating patients through an opt-out method. We registered this study with the University Hospital Medical Information Network (UMIN36150). Declarations: Conflict of interestSatoshi Mochida received lecture fees from Gilead Sciences, Inc., AbbVie GK., ASKA Pharmaceutical Co., Ltd., Toray Industries Inc., Otuska Pharmaceutical Co., Ltd. and Eisai Co., Ltd. Masayuki Kurosaki received lecture fees from Gilead, AbbVie, Eisai, Chugai, AstraZeneca, Lilly and Takeda. Norifumi Kawada received research grants from AstraZeneca plc., Bristol Myers Squibb., Glaxosmithkline plc., MSD co., ltd., Gilead Sciences. Inc. and NovoNordisk pharma Ltd., scholarship grants from AbbVie GK, Eisai Co., Ltd. and Otsuka Pharmaceutical Co. and received lecture fees from AbbVie GK, Gilead Sciences, Inc. and MSD Co., Ltd. Goki Suda received research grants from Gilead Sciences Inc. Hitoshi Yoshiji received lecture fees from Gilead Sci. Naoya Kato received research grants from AbbVie G.K., scholarship grants from Gilead Sciences Inc., and lecture fees from Gilead Sciences, Inc. and AbbVie G.K. Taro Takami received lecture fees from Gilead Sciences, Inc. Yasuhiro Asahina belongs to a donation-funded department funded by Fujirebio Inc. and Abbott Japan LLC. Yoshito Itoh received research grants from Merck Sharp and Dohme., scholarship grants from AbbVie Inc. and Takeda Pharm. Co.Ltd. and lecture fees from AbbVie Inc and Gilead Sciences Inc. Shuji Terai received lecture fees from Otsuka, AbbVie, Asuka, Daiichisankyo, Chiomu Takedansen and Gilead. Yoshiyuki Ueno received lecture fees from AbbVie Inc. Norio Akuta received lecture fees from AbbVie Inc. Tetsuo Takehara received research grants and lecture fees from AbbVie GK. and Gilead Sciences, Inc. All other authors declare that they have no conflicts of interest to disclose.: Trial registration numberUniversity Hospital Medical Information Network (UMIN: 36150). Trial registration number: University Hospital Medical Information Network (UMIN: 36150)."